Skip to main content
LIMN
NASDAQ Life Sciences

Liminatus Pharma Reduces Stockholder Meeting Quorum to One-Third

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
7
Price
$0.24
Mkt Cap
$9.716M
52W Low
$0.21
52W High
$33.66
Market data snapshot near publication time

summarizeSummary

Liminatus Pharma's Board reduced the quorum for stockholder meetings from a majority to one-third, potentially streamlining future corporate actions and altering shareholder influence.


check_boxKey Events

  • Bylaw Amendment Approved

    The Board of Directors approved an amendment to the company's bylaws on February 27, 2026.

  • Quorum Requirement Reduced

    The amendment reduces the quorum for stockholder meetings from a majority to one-third (1/3) of the voting power of outstanding capital stock.

  • Board Retains Authority

    The Board will seek stockholder ratification but has the authority to maintain the amendment even if not approved by stockholders.


auto_awesomeAnalysis

The Board of Directors of Liminatus Pharma, Inc. approved an amendment to its bylaws, significantly reducing the quorum requirement for stockholder meetings from a majority to one-third of the voting power. This change, effective immediately, could streamline future corporate actions by making it easier to achieve a quorum and pass resolutions. While the amendment will be submitted for stockholder ratification, the Board retains the authority to maintain it under Delaware law even if not ratified. This governance change may be viewed as reducing the influence of a dispersed shareholder base.

At the time of this filing, LIMN was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.21 to $33.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LIMN - Latest Insights

LIMN
Mar 31, 2026, 5:28 PM EDT
Filing Type: 10-K
Importance Score:
9
LIMN
Mar 17, 2026, 8:08 AM EDT
Source: GlobeNewswire
Importance Score:
7
LIMN
Mar 04, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
LIMN
Feb 18, 2026, 5:13 PM EST
Filing Type: 8-K
Importance Score:
9
LIMN
Feb 18, 2026, 6:02 AM EST
Filing Type: 424B4
Importance Score:
9
LIMN
Feb 11, 2026, 6:08 AM EST
Filing Type: S-1
Importance Score:
9
LIMN
Feb 09, 2026, 3:01 PM EST
Filing Type: 8-K
Importance Score:
8
LIMN
Jan 26, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
9